Tresperimus (Laboratoires Fournier)

Area of Science:

• Immunology
• Pharmacology
• Transplantation Medicine

Background:

• Organ transplant rejection remains a significant clinical challenge.
• Current immunosuppressive therapies have limitations and side effects.
• Tresperimus (LF-08-0299) is an investigational immunosuppressant developed by Laboratoires Fournier.

Purpose of the Study:

• To evaluate the efficacy and safety of Tresperimus for preventing organ transplant rejection.
• To assess Tresperimus's potential as a first-line immunosuppressive therapy.
• To investigate Tresperimus's activity in preclinical models of transplant rejection.

Main Methods:

• Phase I/II clinical trials initiated in 1995, initially in combination with cyclosporine and tacrolimus.
• Later trials investigated Tresperimus as a first-line therapy.
• Preclinical studies utilizing a rat model of cardiac rejection were conducted.

Main Results:

• Tresperimus demonstrated efficient immunosuppressive activity in a rat model of cardiac rejection.
• Early trials explored its use in graft-versus-host rejection.
• The drug has advanced to Phase III clinical trials in the US and Europe.

Conclusions:

• Tresperimus exhibits promising immunosuppressive properties.
• Further clinical evaluation in Phase III trials is ongoing to confirm its therapeutic potential.
• Laboratoires Fournier is seeking licensees for further development and commercialization.